Equities analysts predict that argenx SE (NASDAQ:ARGX – Get Rating) will post sales of $32.23 million for the current quarter, according to Zacks. Seven analysts have made estimates for argenx’s earnings. The lowest sales estimate is $23.13 million and the highest is $41.50 million. argenx reported sales of $320.06 million in the same quarter last year, which indicates a negative year over year growth rate of 89.9%. The company is scheduled to announce its next quarterly earnings report on Monday, January 1st.
On average, analysts expect that argenx will report full year sales of $163.14 million for the current year, with estimates ranging from $124.50 million to $197.20 million. For the next financial year, analysts forecast that the business will post sales of $457.62 million, with estimates ranging from $360.27 million to $568.20 million. Zacks Investment Research’s sales calculations are an average based on a survey of analysts that that provide coverage for argenx.
argenx (NASDAQ:ARGX – Get Rating) last announced its quarterly earnings results on Thursday, May 5th. The company reported ($4.36) EPS for the quarter, beating analysts’ consensus estimates of ($5.08) by $0.72. argenx had a negative net margin of 147.47% and a negative return on equity of 32.54%. During the same quarter last year, the firm posted ($0.81) earnings per share.
A number of research firms have issued reports on ARGX. Morgan Stanley raised shares of argenx from an “equal weight” rating to an “overweight” rating and set a $375.00 price objective on the stock in a report on Tuesday, May 3rd. JPMorgan Chase & Co. lifted their price objective on shares of argenx from €350.00 ($372.34) to €370.00 ($393.62) and gave the stock an “overweight” rating in a report on Friday, May 6th. SVB Leerink reissued an “outperform” rating on shares of argenx in a report on Tuesday. Deutsche Bank Aktiengesellschaft raised shares of argenx from a “hold” rating to a “buy” rating in a report on Friday, May 13th. Finally, HC Wainwright reissued a “buy” rating and issued a $400.00 price target on shares of argenx in a report on Friday, March 4th. One investment analyst has rated the stock with a sell rating, one has given a hold rating, seventeen have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus target price of $360.94.
Shares of ARGX stock opened at $315.97 on Friday. The firm has a market capitalization of $16.94 billion, a PE ratio of -27.38 and a beta of 1.11. The firm has a fifty day simple moving average of $311.00 and a two-hundred day simple moving average of $301.22. argenx has a 12 month low of $249.50 and a 12 month high of $356.78.
Large investors have recently added to or reduced their stakes in the company. TD Asset Management Inc. lifted its stake in argenx by 48.0% in the fourth quarter. TD Asset Management Inc. now owns 200,878 shares of the company’s stock worth $70,345,000 after acquiring an additional 65,117 shares during the period. Ensign Peak Advisors Inc raised its holdings in argenx by 96.5% in the fourth quarter. Ensign Peak Advisors Inc now owns 18,520 shares of the company’s stock worth $6,485,000 after purchasing an additional 9,097 shares in the last quarter. Raymond James Financial Services Advisors Inc. bought a new position in argenx in the fourth quarter worth $850,000. UBS Group AG raised its holdings in argenx by 38.9% in the third quarter. UBS Group AG now owns 12,511 shares of the company’s stock worth $3,779,000 after purchasing an additional 3,501 shares in the last quarter. Finally, Skandinaviska Enskilda Banken AB publ raised its holdings in argenx by 10.8% in the fourth quarter. Skandinaviska Enskilda Banken AB publ now owns 10,935 shares of the company’s stock worth $3,860,000 after purchasing an additional 1,068 shares in the last quarter. 58.76% of the stock is owned by hedge funds and other institutional investors.
argenx Company Profile (Get Rating)
argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, and chronic inflammatory demyelinating polyneuropathy in Phase III clinical trials; bullous pemphigoid and idiopathic inflammatory myopathy in Phase II/III clinical trials; and ENHANZE SC in Pre-clinical study.
Get a free copy of the Zacks research report on argenx (ARGX)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for argenx Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for argenx and related companies with MarketBeat.com’s FREE daily email newsletter.
Tags: #Million #Sales #Expected #argenx #NASDAQARGX #Quarter #Defense #World